# Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Source: https://onco.cc/trials/nct05826535/  
OnCo record `nct05826535` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Rondecabtagene autoleucel, Fludarabine, Cyclophosphamide in hodgkin lymphoma and non-hodgkin lymphoma, run by Lyell Immunopharma, Inc., now recruiting.

## Summary

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma is a phase 1/2 interventional study registered as NCT05826535 by Lyell Immunopharma, Inc., with 270 participants planned, started 2023-05-09 and due to reach its primary completion in 2028-12-31. Interventions recorded: Rondecabtagene autoleucel (ronde-cel), Fludarabine, Cyclophosphamide. Conditions listed: Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05826535
- Phase: 1/2
- Setting: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of Rondecabtagene Autoleucel, a CD19/CD20 Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy in Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
- Sponsor: Lyell Immunopharma, Inc.
- Enrolled: 270

## Sources

- ClinicalTrials.gov NCT05826535: https://clinicaltrials.gov/study/NCT05826535

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/), [Rondecabtagene autoleucel](https://onco.cc/drugs/rondecabtagene-autoleucel/)
- companies: [Lyell Immunopharma](https://onco.cc/companies/lyell-immunopharma/)

---
JSON: https://onco.cc/api/v1/entities/nct05826535.json